Form 4: Director Stock Option Grant at 4D Molecular Therapeutics

Susannah Gray, a Director at 4D Molecular Therapeutics, received a stock option grant for 50,000 shares.

Summary

• Susannah Gray, a Director at 4D Molecular Therapeutics, Inc. (FDMT), was granted stock options.
• The grant includes the right to purchase 50,000 shares of common stock at an exercise price of $9.42 per share.
• The stock options were granted on June 17, 2026.
• These options vest over a period, with 1/3 vesting on June 17, 2027, and the remainder vesting in equal monthly installments until fully vested on June 17, 2029.
• Vesting is contingent upon continued service to the company.
• The options will also vest in full upon a Change in Control event.
• The grant was made automatically under the company's non-employee director compensation program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation event for a director rather than a significant financial event or strategic shift.

Positives

• Director Susannah Gray received a significant stock option grant, indicating continued investment and alignment with the company's long-term success.
• The stock option grant is structured with a vesting schedule, incentivizing continued service and commitment from the director.
• The potential for full vesting upon a Change in Control event aligns the director's interests with a potential future strategic transaction.

Risks

• The value of the stock options is subject to the future performance of 4D Molecular Therapeutics' stock price.
• Vesting is contingent on continued service, meaning any departure from the company before full vesting would result in forfeiture of unvested options.
• The stock options have an expiration date of June 16, 2036, and will be forfeited if not exercised by then.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the market value of its common stock. The vesting schedule indicates a long-term commitment and expectation of value creation over the next several years.

Industry Context

StockSavvy.ai notes that stock option grants to directors are a common practice in the biotechnology and pharmaceutical sectors, serving as a key component of executive and director compensation to align incentives with shareholder value creation and long-term company growth.

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholders, potentially encouraging decisions that benefit long-term stock value. However, it also represents potential future dilution if options are exercised.
• Employees: The compensation structure for directors is separate from employee compensation, but a successful company performance incentivized by such grants can indirectly benefit employees through job security and potential bonuses.
• Management: The grant is part of the overall compensation strategy for key personnel, reinforcing alignment.

Next Steps

• Susannah Gray will continue to serve the company, working towards the vesting of her stock options.
• The company will continue its operations, with the director's compensation structure in place.

Key Dates

Keywords

stock options, director compensation, 4D Molecular Therapeutics, FDMT, insider trading, equity award, vesting schedule, change in control